C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
12 déc. 2023 16h01 HE
|
C4 Therapeutics, Inc.
Data Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity Completed Monotherapy Dose Escalation Demonstrates Anti-Myeloma...
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)
12 déc. 2023 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
28 nov. 2023 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
20 nov. 2023 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
01 nov. 2023 07h00 HE
|
C4 Therapeutics, Inc.
Portfolio Decision to Prioritize Ongoing Phase 1/2 Trials of CFT7455, an IKZF1/3 Degrader, and CFT1946, a BRAF V600 Degrader CFT8634, a BRD9 Degrader, Will Not Advance in Synovial Sarcoma and...
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma
11 oct. 2023 07h00 HE
|
C4 Therapeutics, Inc.
CFT8634 Phase 1 Dose Escalation Data to be Presented at the Connective Tissue Oncology Society Annual Meeting on November 2, 2023 CFT7455 Monotherapy Phase 1 Dose Escalation Complete in...
C4 Therapeutics Announces Chief Financial Officer Succession
05 sept. 2023 16h01 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
08 août 2023 07h00 HE
|
C4 Therapeutics, Inc.
Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared Ongoing Phase 1/2 Clinical Trials of...
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 juil. 2023 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
05 juil. 2023 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)...